Corcept Therapeutics: FDA Decision in December - The Catalyst for the $165 Price Target?
Reading Time: 2 minutes
Analysts at Piper Sandler confirm the buy recommendation for Corcept Therapeutics with a price target of $165. Revenue forecasts for 2026 have been raised following recent approval successes. An important approval decision for Relacorilant is expected in mid-December 2026. Drug Development for Endocrine Diseases The business model of Corcept Therapeutics (CORT) focuses on the development of glucocorticoid receptor antagonists. These drugs primarily address metabolic disorders and oncological indications. A central growth trend is the...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
